How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fixed-combination-latanoprost-timolol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

fixed combination latanoprost-timolol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

fixed combination latanoprost-timolol (fixed combination latanoprost-timolol) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analog and beta-blocker combination. Area: Ophthalmology.

phase 3 Prostaglandin analog and beta-blocker combination Beta-adrenergic receptors, Prostaglandin receptors Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

fixed combination latanoprost-timolol (fixed combination latanoprost-timolol) — Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Latanoprost-timolol is a fixed combination of a prostaglandin analog and a beta-blocker that works by reducing intraocular pressure in the eye.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
fixed combination latanoprost-timolol TARGET	fixed combination latanoprost-timolol	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	phase 3	Prostaglandin analog and beta-blocker combination	Beta-adrenergic receptors, Prostaglandin receptors
Travoprost and Timolol	Travoprost and Timolol	Afyon Kocatepe University Hospital	marketed	Prostaglandin analog and beta-blocker combination	FP receptor (travoprost); beta-2 adrenergic receptor (timolol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analog and beta-blocker combination class)

Afyon Kocatepe University Hospital · 1 drug in this class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). fixed combination latanoprost-timolol — Competitive Intelligence Brief. https://druglandscape.com/ci/fixed-combination-latanoprost-timolol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab